117 related articles for article (PubMed ID: 22609576)
1. Acetylcholinesterase inhibitors reduce spreading activation in dementia.
Foster PS; Branch KK; Witt JC; Giovannetti T; Libon D; Heilman KM; Drago V
Neuropsychologia; 2012 Jul; 50(8):2093-9. PubMed ID: 22609576
[TBL] [Abstract][Full Text] [Related]
2. Recall of word lists is enhanced with increased spreading activation.
Foster PS; Roosa KM; Drago V; Branch K; Finney G; Heilman KM
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2013; 20(5):553-66. PubMed ID: 23298321
[TBL] [Abstract][Full Text] [Related]
3. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
4. Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors.
Klugman A; Naughton DP; Isaac M; Shah I; Petroczi A; Tabet N
J Alzheimers Dis; 2012; 30(3):467-74. PubMed ID: 22451323
[TBL] [Abstract][Full Text] [Related]
5. Spreading activation of lexical-semantic networks in Parkinson's disease.
Foster PS; Drago V; FitzGerald DB; Skoblar BM; Crucian GP; Heilman KM
Neuropsychologia; 2008; 46(7):1908-14. PubMed ID: 18325544
[TBL] [Abstract][Full Text] [Related]
6. Differential lexical and semantic spreading activation in Alzheimer's disease.
Foster PS; Drago V; Yung RC; Pearson J; Stringer K; Giovannetti T; Libon D; Heilman KM
Am J Alzheimers Dis Other Demen; 2013 Aug; 28(5):501-7. PubMed ID: 23800553
[TBL] [Abstract][Full Text] [Related]
7. Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study.
Tamimi I; Ojea T; Sanchez-Siles JM; Rojas F; Martin I; Gormaz I; Perez A; Dawid-Milner MS; Mendez L; Tamimi F
J Bone Miner Res; 2012 Jul; 27(7):1518-27. PubMed ID: 22467182
[TBL] [Abstract][Full Text] [Related]
8. Automatic and attentional mechanisms of semantic priming in Alzheimer's disease.
Nebes RD; Brady CB; Huff FJ
J Clin Exp Neuropsychol; 1989 Mar; 11(2):219-30. PubMed ID: 2925832
[TBL] [Abstract][Full Text] [Related]
9. [Cholinergic deficiency syndrome as an indicator for the cholinesterase inhibitors].
Lemstra AW; Eikelenboom P; van Gool WA
Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2201-3. PubMed ID: 14640055
[TBL] [Abstract][Full Text] [Related]
10. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.
Relkin NR
Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789
[TBL] [Abstract][Full Text] [Related]
11. [Impact of treatment with acetylcholinesterase inhibitors, valproic acid and antipsychotics on aggressive behaviour in Alzheimer's type dementia].
Bidzan L; Grabowski J; Dutczak B; Bidzan M
Psychiatr Pol; 2012; 46(3):361-72. PubMed ID: 23045890
[TBL] [Abstract][Full Text] [Related]
12. Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French REAL.FR cohort.
Gillette-Guyonnet S; Cortes F; Cantet C; Vellas B;
J Nutr Health Aging; 2005; 9(2):69-73. PubMed ID: 15791348
[TBL] [Abstract][Full Text] [Related]
13. Multidimensional measures of person knowledge and spatial associative learning: can these be applied to the differentiation of Alzheimer's disease from frontotemporal and vascular dementia?
Clague F; Dudas RB; Thompson SA; Graham KS; Hodges JR
Neuropsychologia; 2005; 43(9):1338-50. PubMed ID: 15949518
[TBL] [Abstract][Full Text] [Related]
14. The impact of lexical-semantic impairment and of executive dysfunction on the word reading performance of patients with probable Alzheimer dementia.
Colombo L; Fonti C; Cappa S
Neuropsychologia; 2004; 42(9):1192-202. PubMed ID: 15178171
[TBL] [Abstract][Full Text] [Related]
15. Effects of donepezil on verbal memory after semantic processing in healthy older adults.
FitzGerald DB; Crucian GP; Mielke JB; Shenal BV; Burks D; Womack KB; Ghacibeh G; Drago V; Foster PS; Valenstein E; Heilman KM
Cogn Behav Neurol; 2008 Jun; 21(2):57-64. PubMed ID: 18541979
[TBL] [Abstract][Full Text] [Related]
16. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle.
Pakrasi S; Mukaetova-Ladinska EB; McKeith IG; O'Brien JT
Int J Geriatr Psychiatry; 2003 Oct; 18(10):879-86. PubMed ID: 14533120
[TBL] [Abstract][Full Text] [Related]
17. Use of antidementia drugs in frontotemporal lobar degeneration.
López-Pousa S; Calvó-Perxas L; Lejarreta S; Cullell M; Meléndez R; Hernández E; Bisbe J; Perkal H; Manzano A; Roig AM; Turró-Garriga O; Vilalta-Franch J; Garre-Olmo J;
Am J Alzheimers Dis Other Demen; 2012 Jun; 27(4):260-6. PubMed ID: 22605780
[TBL] [Abstract][Full Text] [Related]
18. Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors?
Small DH
Expert Opin Emerg Drugs; 2005 Nov; 10(4):817-25. PubMed ID: 16262564
[TBL] [Abstract][Full Text] [Related]
19. Use of drugs with anticholinergic properties among nursing home residents with dementia: a national analysis of Medicare beneficiaries from 2007 to 2008.
Palmer JB; Albrecht JS; Park Y; Dutcher S; Rattinger GB; Simoni-Wastila L; Walker LD; Zuckerman IH
Drugs Aging; 2015 Jan; 32(1):79-86. PubMed ID: 25491558
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in dementia: care recipient and caregiver perceptions of quality of life in dementia: the LASER-AD study.
Hoe J; Katona C; Orrell M; Livingston G
Int J Geriatr Psychiatry; 2007 Oct; 22(10):1031-6. PubMed ID: 17380488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
